Table 4

Types and clinical use of anti-HGF mAbs and multi-kinase inhibitors

DrugType, target and referencesDisease, stage and references
Ficlatuzumab/AV-299mAb against HGF90Solid tumours (Phase I/II), NSCLC (combined with gefitinib, Phase II).90
Rilotumumab/AMG 102mAb against HGF90Multiple tumour types including: RCC (Phase II), prostate cancer (combined with mitoxantrone and prednisone, Phase II).91 92
Onartuzumab/PRO143966mAb against Met93NSCLC (combination with erlotinib, Phase II), solid tumours (Phase I)94 95
Cabozantinib/BMS-907351TKI of Met, VEGFR2, RET, Kit, AXL and FLT396Multiple tumour types including: prostate, breast cancer, NSCLC (Phase II)97 98
Crizotinib/PF-02341066TKI of Met, ALK and ROS1 99NSCLC (Phase III), GEC (Phase I)99 100
Tivantinib/ARQ 197TKI of Met101HCC (Phase II), NSCLC (Phase II), gastric cancer (Phase II)102–104
Foretinib/GSK1363089TKI of Met, VEGFR2, RON, Kit and AXL105Gastric cancer (Phase II), solid tumours (Phase I)105 106
  • ALK, anaplastic lymphoma kinase; FLT3, FMS-like tyrosine kinase-3; GEC, gastroesophageal cancer; HCC, hepatocellular carcinoma; HGF, hepatocyte growth factor; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; RON, Recepteur d'Origine Nantais; VEGFR, vascular endothelial growth factor receptor; mAb, monoclonal antibody; TKI, tyrosine kinase inhibitors; RET, rearranged during transfection; ROS1, c-ros oncogene 1; Met, hepatocyte-derived growth factor receptor.